Table 1.
Clinical characteristics of attacks requiring orotracheal intubation versus attacks not requiring orotracheal intubation
| All attacks, N = 73 | OTI-attacks, N = 8 (11.0%) | Non-OTI-attacks, N = 65 (89.0%) | P-value | |
|---|---|---|---|---|
| Gender: female/male | 64 (87.7) | 7 (87.5) | 57 (87.7) | 0.925 |
| Place of birth | – | |||
| France—metropolitan area | 34 (46.6) | 1 (12.5) | 33 (50.8) | |
| France–West indies–Guyana | 6 (8.2) | 4 (50.0) | 2 (3.1) | |
| Asia | 6 (8.2) | 0 (0.0) | 6 (9.2) | |
| North Africa | 6 (8.2) | 0 (0.0) | 6 (9.2) | |
| Sub-Saharan Africa | 20 (27.4) | 2 (25.0) | 18 (27.7) | |
| Middle East | 1 (1.4) | 1 (12.5) | 0 (0.0) | |
| Age at start of the disease, years, median (IQR) | 33.20 [21.30, 46.90] | 47.15 [33.18, 55.70] | 32.90 [19.60, 43.40] | 0.662 |
| Age at attack onset, years | 43 (31–53) | 50 (42–56) | 43 (28–53) | 0.834 |
| First attack of NMOSD-AQP4 disease | 22 (30.1) | 4 (50) | 18 (27.7) | 0.592 |
| Attack occurring in the first 6 months of NMOSD-AQP4 disease | 28 (38.9) | 7 (87.5) | 21 (32.8) | 0.411 |
| Any active NMOSD disease modifying therapy (DMT)a | 36 (49.3) | 0 (0) | 36 (55.4) | – |
| Type of DMT | ||||
| Azathioprine | 8 (11) | – | 8 (12.3) | |
| Mycophenolate mofetil | 11 (15.1) | – | 11 (16.9) | |
| Rituximab | 8 (11) | – | 8 (12.3) | |
| Cyclophosphamide | 3 (4.1) | – | 3 (4.6) | |
| Methotrexate | 4 (5.5) | – | 4 (6.2) | |
| TPE | 6 (8.2) | – | 6 (9.2) | |
| EDSS before attack | 2.0 (0–3.5) | 1.0 (0–3.5) | 2.0 (0–3.5) | 0.460 |
| Modified Rankin scale before attack | 1 (0–2) | 0.5 (0–3.25) | 1 (0–2) | 0.380 |
| Clinical examination at the hospital entry | ||||
| EDSS at admission | 6.0 (3.5–8) | 7.5 (6.0–8.5) | 6.0 (3.5–8) | 0.029 |
| Lower limb paresis | 46 (63) | 6 (75) | 40 (61.5) | 0.460 |
| Upper limb paresis | 25 (34.2) | 6 (75) | 19 (29.2) | 0.366 |
| Dyspnea (number of patients with available data) | 7 (9.7) (71) | 3 (50) (6) | 4 (6.6) (65) | 0.002 |
Results are expressed in median (interquartile range) or N (%) unless otherwise specified
NA number of observations non available, OTI orotracheal intubation, DMT disease modifying therapy
P-value is estimated with binomial generalized linear mixed model, with a random intercept for patient ID. Due to separation issues, p-value has not been estimated for some variables
aActive DMT was defined if it has been received for at least 3 months before the attack first symptoms